Preclinical evidence demonstrates that α-emitter RPT depletes regulatory T cells (Tregs) in TME while promoting CD8+ effector activation, for example, 225Ac-NM600 significantly reduced Treg infiltration and increased CD44+, CD69+, Ki67+, and CD8+ populations in murine prostate cancer models [407]. Here, CD8A is linked to prostate cancer.